New drug combo targets tough digestive cancers in key trial
Disease control
Recruiting now
This study is testing whether a new drug called LM-302, when combined with other cancer treatments, can help control advanced digestive tract cancers that have a specific marker called CLDN18.2. It is for adults whose cancer has continued to grow despite standard first-line treat…
Phase: PHASE2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC